Title:
BENZOISOTHIAZOLE HYPOXIA-INDUCIBLE FACTOR-2 AGONIST COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, PREPARATION METHOD AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/242462
Kind Code:
A1
Abstract:
Disclosed in the present invention are a benzoisothiazole hypoxia-inducible factor-2 (HIF-2) agonist compound or a pharmaceutically acceptable salt thereof. The compound can stimulate the HIF-2 transcriptional activity and enhance generation and secretion of erythropoietin, thereby promoting generation of erythrocytes. The benzoisothiazole HIF-2 agonist compound or the pharmaceutically acceptable salt thereof prepared in the present invention can be used in combination with a prolyl hydroxylase inhibitor to realize a synergistic effect in improving the HIF-2 transcriptional activity, and can be used for treating HIF-2 related diseases, such as ischemic diseases.
Inventors:
ZHANG XIAOJIN (CN)
YU YANCHENG (CN)
LIU SIMENG (CN)
YU QUANWEI (CN)
WU CHENYANG (CN)
YU YANCHENG (CN)
LIU SIMENG (CN)
YU QUANWEI (CN)
WU CHENYANG (CN)
Application Number:
PCT/CN2022/090943
Publication Date:
November 24, 2022
Filing Date:
May 05, 2022
Export Citation:
Assignee:
UNIV CHINA PHARMA (CN)
International Classes:
A61K31/428; C07D275/04; A61K31/437; A61K31/4418; A61K31/472; A61K31/513; A61K31/5377; A61P7/06; A61P9/10; C07D275/06; C07D417/12
Foreign References:
| CN113200938A | 2021-08-03 | |||
| JP2000159610A | 2000-06-13 |
Other References:
YU, YANCHENG ET AL.: "Insight into the Binding Mode of HIF-2 Agonists through Molecular Dynamic Simulations and Biological Validation", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 211, 7 November 2020 (2020-11-07), XP086465940, DOI: 10.1016/j.ejmech.2020.112999
CHEN, HAO ET AL.: "Design, Synthesis, and Structure-Activity Relationship of Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction Inhibitors Bearing a Benzo[d]isothiazole Scaffold", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 217, 15 March 2021 (2021-03-15), XP086577214, DOI: 10.1016/j.ejmech.2021.113377
YU YANCHENG, YANG FULAI, YU QUANWEI, LIU SIMENG, WU CHENYANG, SU KAIJUN, YANG LE, BAO XIAOQIAN, LI ZHIHONG, LI XIANG, ZHANG XIAOJI: "Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 23, 28 October 2021 (2021-10-28), pages 17384 - 17402, XP093008181
CHEN, HAO ET AL.: "Design, Synthesis, and Structure-Activity Relationship of Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction Inhibitors Bearing a Benzo[d]isothiazole Scaffold", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 217, 15 March 2021 (2021-03-15), XP086577214, DOI: 10.1016/j.ejmech.2021.113377
YU YANCHENG, YANG FULAI, YU QUANWEI, LIU SIMENG, WU CHENYANG, SU KAIJUN, YANG LE, BAO XIAOQIAN, LI ZHIHONG, LI XIANG, ZHANG XIAOJI: "Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 23, 28 October 2021 (2021-10-28), pages 17384 - 17402, XP093008181
Attorney, Agent or Firm:
NANJING SUGAO PATENT AND TRADEMARK FIRM ( ORDINARY PARTNERSHIP ) (CN)
Download PDF: